Infectious Respiratory Disease Diagnostics Market To Reach $15.70 Billion By 2033

Infectious Respiratory Disease Diagnostics Market Growth & Trends

The global infectious respiratory disease diagnostics market size is expected to reach USD 15.70 billion by 2033, registering a CAGR of 2.90% from 2026 to 2033, according to a new report by Grand View Research, Inc. The decline in market size is majorly attributed to the decline in COVID-19 testing. However, the market without the impact of COVID-19 is expected to grow over the forecast years. The growth can be attributed to an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & nonprofit organizations to introduce novel & innovative products to address the increasing demand. For instance, the global investment in tuberculosis R&D reached USD 915 million, and around USD 401 million was spent by the U.S. government on TB research in 2020.

During the forecast period, the global industry is expected to be driven by the rising incidence of infectious respiratory disorders, such as tuberculosis, RSV, and influenza. According to the UN, pneumonia affects around 4.2 million people every year. Key players are developing innovative techniques to improve production for meeting the growing demand in diagnostics and consumables for the diagnosis of infectious diseases. For instance, OPT Industries Inc. has introduced InstaSwab by utilizing the 3D printing system to address supply shortages of sample collection kits due to the COVID-19 pandemic. These swabs are made of woven lattices to absorb and release more fluid than conventional swabs. Companies are advancing their diagnosis products by using new techniques to gain target-specific and accurate results.

Canon Inc. announced the development of a built-in AEC assistance for digital X-rays in March 2021. The X-ray image sensor enables users to perform picture production and real-time detection of images corresponding to emitted X-rays. Furthermore, in May 2021, the University of California developed an ultrasensitive molecular test to identify the presence of SARS-CoV-2 and influenza A antigens using chip technology. In addition, companies are also launching multiplex tests for the simultaneous diagnosis of RSV, influenza, and COVID-19 respiratory diseases. RT-PCR tests are considered the gold standard for the diagnosis of COVID-19 in patients. However, high prices associated with molecular tests are one of the major factors impeding this market.

The lack of comparable products is another reason for hiked prices. This problem is further compounded by the significant variations in prices for different applications of each molecular diagnostic product. Companies are adopting strategies, such as new product launches and partnerships, to increase the penetration of infectious respiratory disease diagnostics products. For instance, in August 2021, Thermo Fisher Scientific Inc. received EUA for the introduction of two COVID-19 diagnostic products, TaqPath COVID-19 RNase P Combo Kit and TaqPath COVID-19 Fast PCR Combo Kit, in the U.S. market.

 Request a free sample copy or view report summary: Infectious Respiratory Disease Diagnostics Market Report

Infectious Respiratory Disease Diagnostics Market Report Highlights

• Based on product, the reagent segment dominated the global market and accounted for the largest revenue share of 65.38% 2025. The instrument segment is anticipated to grow at a considerable rate of 2.67% CAGR over the forecast period.

• Based on technology, the diagnostics segment accounted for 67.63% of the overall market share in 2025. The rapid/point-of-care diagnostics segment is anticipated to grow at the fastest rate of 3.54% CAGR over the forecast period.

• Based on application, the COVID-19 segment dominated the global market in 2025, accounting for 89.24% of the revenue. Meanwhile, the tuberculosis segment is anticipated to grow at the fastest rate of 9.74% CAGR over the forecast period.

• Based on end-use, the diagnostic laboratories segment led the market, accounting for 38.62% of the revenue share in 2025. The hospital segment is projected to experience substantial growth during the forecast period.

• North America infectious respiratory disease diagnostics market dominated the overall global market and accounted for 44.62% of the revenue share in 2025. The infectious respiratory disease diagnostics market in the Asia Pacific is experiencing the fastest growth, driven by significant advancements in terms of technology.

Infectious Respiratory Disease Diagnostics Market Segmentation

Grand View Research has segmented global infectious respiratory disease diagnostics market report based on technology, pathogen, end-use, and region:

Infectious Respiratory Disease Diagnostics Product Outlook (Revenue, USD Million, 2021 - 2033)

• Instruments

• Reagents

• Services

Infectious Respiratory Disease Diagnostics Application Outlook (Revenue, USD Million, 2021 - 2033)

• COVID-19

• Influenza

• Respiratory Syncytial Virus (RSV)

• Tuberculosis

• Non-tuberculosis Mycobacterium Testing

• Bacterial Pneumonia Testing

• Other Respiratory Disease Testing

Infectious Respiratory Disease Diagnostics Technology Outlook (Revenue, USD Million, 2021 - 2033)

• Immunoassay

• Molecular Diagnostics

• Microbiology

• Rapid/Point-of-Care Diagnostics

• Other Technologies

Infectious Respiratory Disease Diagnostics End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospitals

• Diagnostic Laboratories

• Clinics

• Research Institutes

Infectious Respiratory Disease Diagnostics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Infectious Respiratory Disease Diagnostics Market

• Abbott

• Bio-Rad Laboratories, Inc

• Siemens Healthineers AG

• bioMérieux

• BD

• QIAGEN

• QuidelOrtho Corporation

• F. Hoffmann-La Roche

• Koninklijke Philips N.V.

• Cepheid (Danaher Corporation)

• Seegene Inc.

• EliTechGroup (Bruker Corporation)

• CERTEST BIOTEC

• Thermo Fisher Scientific, Inc.